Patients with type 2 diabetes who are uptitrating to a maximum metformin dose benefit from improved glycemic control when they simultaneously initiate sitagliptin, randomized trial findings suggest.
Giving pregnant obese women metformin in addition to dietary and lifestyle advice does not reduce the likelihood of them having a baby with a high birthweight, show the results of the GRoW randomized trial.
The RISE investigators have reported a continued lack of effect of early intensive therapy on beta-cell function decline in children with prediabetes or early type 2 diabetes.
Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of sodium-glucose co-transporter-2 inhibitors in patients affected by acute coronary syndromes.
With the arrival of slow-release formulations of metformin and the relaxation of guidelines concerning its use in patients with kidney disease, Carol Wysham explains how the population of patients who might benefit from this medication has expanded.
Twenty years after the publication of the primary findings, medwireNews talks to longtime UKPDS investigator Professor David Matthews (University of Oxford, UK) about the struggles of the team to bring the trial to completion and the impact of the findings on diabetes care.
medwireNews outlines which medications have so far been tested as adjunct treatments for type 1 diabetes and summarizes the key trial data showing their benefits or otherwise.